Insider Selling: Emergent Biosolutions (NYSE:EBS) Director Sells $126,202.00 in Stock

Emergent Biosolutions Inc. (NYSE:EBS) Director Donald Degolyer sold 17,800 shares of the firm’s stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $7.09, for a total transaction of $126,202.00. Following the completion of the transaction, the director owned 111,921 shares in the company, valued at $793,519.89. This represents a 13.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Up 3.2%

Shares of NYSE EBS opened at $7.03 on Friday. The firm’s fifty day moving average is $6.08 and its 200 day moving average is $7.45. Emergent Biosolutions Inc. has a 52 week low of $4.36 and a 52 week high of $14.06. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70. The company has a market cap of $360.19 million, a price-to-earnings ratio of -1.98 and a beta of 2.28.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.68. The business had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. On average, equities research analysts expect that Emergent Biosolutions Inc. will post 0.13 earnings per share for the current year.

Analysts Set New Price Targets

EBS has been the topic of a number of research analyst reports. Weiss Ratings upgraded Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st. JPMorgan Chase & Co. assumed coverage on Emergent Biosolutions in a research note on Friday, August 21st. They set an “underweight” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Emergent Biosolutions in a report on Wednesday, September 9th. Finally, Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Emergent Biosolutions has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC purchased a new position in shares of Emergent Biosolutions during the second quarter valued at approximately $29,000. Public Employees Retirement System of Ohio bought a new position in shares of Emergent Biosolutions during the second quarter valued at $36,000. Legal & General Group Plc purchased a new position in shares of Emergent Biosolutions in the 2nd quarter worth about $44,000. Tocqueville Asset Management L.P. bought a new position in Emergent Biosolutions in the 2nd quarter worth about $93,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Emergent Biosolutions during the 2nd quarter valued at about $115,000. 78.40% of the stock is currently owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.

Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.